The Pennant Group (PNTG) Q2 2024 earnings summary

Executive summary

• Achieved record Q2 2024 results with revenue up 27.6% to $168.7 million, driven by strong growth in home health, hospice, and senior living, and supported by both organic and acquisitive expansion.

• Net income rose to $5.7 million, up 103.4% year-over-year; GAAP diluted EPS was $0.18, adjusted EPS was $0.24.

• Added over 2,200 lives through acquisitions and organic growth, plus 4,000 under a new management agreement, representing a 50%+ increase in daily lives served since end of 2023.

• Announced and closed several key transactions, including the largest acquisition in company history (Signature Healthcare at Home) and a major management agreement with Hartford HealthCare.

• Growth supported by the addition of 16 home health and hospice agencies and 3 senior living communities over the past year.

Financial highlights

• Q2 2024 revenue reached $168.7 million, up 27.6% year-over-year; net income was $5.7 million.

• Adjusted EBITDA was $13.2 million; adjusted EPS was $0.24, both exceeding consensus.

• Six-month revenue reached $325.7 million, up 25.9% from the prior year period.

• Cash flows from operations totaled $11 million year-to-date, with $10.5 million in Q2.

• Cash at June 30, 2024 was $3.0 million, with $62.8 million available on the revolving credit facility.

Outlook and guidance

• Raised full-year 2024 revenue guidance to $654–$694.5 million and adjusted EPS to $0.89–$0.95.

• Full-year adjusted EBITDA projected at $50.7–$53.8 million, reflecting continued strong performance and accretive acquisitions.

• Midpoint of new EPS guidance is a 5.7% increase over original 2024 guidance and 26% above 2023 adjusted earnings.

• Guidance incorporates current operations, organic growth, and known transactions, but excludes unannounced acquisitions and certain one-time items.

• Management expects continued growth from recent acquisitions and improved occupancy, but notes that inflation and competitive pressures may impact margins.